Skip to main content

Closed

LYEL: Lyell Immunopharma, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Operating margin-618909.7%

ROIC-59.4%

Financially safe

Stretched

Debt / equity0.18×

Interest coverage0.0×

Current ratio7.23×

Lyell Immunopharma, Inc.

LYELNASDAQ·USD·Closed

Lyell Immunopharma, Inc.

LYELNASDAQ·USD·Closed

$12.94

−5.69%

$12.94

−$0.78 (5.69%)

52W Range

10thpctl

Volume

0.78×avg

Mkt Cap

317.09MUSD

P/E

-0.8TTM

Div Yield

–ann

52W Range

10thpctl

Volume

0.78×avg

Market Cap

317.09MUSD

P/E Ratio

-0.8TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings